Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 6/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | MTOR | P42345 | 5/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 3/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4910489 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMTORHDAC8 | |
| SCHEMBL4910494 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AMTORHDAC8 | |
| SCHEMBL4907788 | 0.86 | HDAC8 (0.52) | SMN1; SMN2NPC1RAB9AMTORHDAC8 | |
| SCHEMBL4907770 | 0.86 | HDAC8 (0.52) | SMN1; SMN2NPC1RAB9AMTORHDAC8 | |
| SCHEMBL4907784 | 0.86 | HDAC8 (0.52) | SMN1; SMN2NPC1RAB9AMTORHDAC8 | |
| SCHEMBL4912974 | 0.84 | HDAC8 (0.51) | SMN1; SMN2NPC1RAB9AHDAC8CYP1A2 | |
| SCHEMBL4912976 | 0.84 | HDAC8 (0.51) | SMN1; SMN2NPC1RAB9AHDAC8CYP1A2 | |
| SCHEMBL1669309 | 0.84 | HDAC8 (0.51) | SMN1; SMN2NPC1RAB9AHDAC8CYP1A2 | |
| SCHEMBL684482 | 0.82 | KDM1A (0.61) | SMN1; SMN2NPC1RAB9AMTORHDAC8 | |
| SCHEMBL1670113 | 0.80 | MAPT (0.70) | SMN1; SMN2HDAC8CYP1A2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | claimed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-08-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219543-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISORDERS OF GLUCOSE HOMEOSTASIS | CFTR, IAPP, GPR119 | SMN1; SMN2 1964/4885NPC1 90/4885RAB9A 2267/4885 |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | SMN1; SMN2 4722/4885NPC1 228/4885RAB9A 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.